Nasus Pharma (NSRX) Retained Earnings (2024 - 2025)
Nasus Pharma (NSRX) reported Retained Earnings of -$18.5 million for Q4 2025, down 46.24% on a YoY basis from -$34.5 million in Q4 2024, and down 33.08% quarter-over-quarter from -$13.9 million in Q2 2025.
Nasus Pharma (NSRX) Retained Earnings (2024 - 2025) Analysis & Trends
Nasus Pharma has reported Retained Earnings for 2 years, with the latest figure at -$18.5 million in Q4 2025.
- For the quarter ending Q4 2025, Retained Earnings fell 46.24% year-over-year to -$18.5 million; the trailing twelve-month figure through Dec 2025 stood at -$18.5 million (down 46.24% YoY), and the FY2025 full-year result was -$18.5 million, down 46.24% from the prior year.
- Retained Earnings for Q4 2025 stood at -$18.5 million, down from -$13.9 million in the prior quarter.
- The five-year high for Retained Earnings was -$12.7 million in Q4 2024, with the low at -$18.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 1.90 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 29.51 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -14.83 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -17.87 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 66.72 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -190.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 78.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -7.20 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -1.37 Bn |
| 10 | Nasus Pharma | 23.47 Mn | 19.18 Mn | - | -18.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -18.52 Mn |
| Jun 30, 2025 | -13.92 Mn |
| Dec 31, 2024 | -12.66 Mn |